Traditional IRA
Rollover IRA
Roth IRA


Expert Advice
Simple Plan
Keogh Plan
401K Plan
SEP Plan


LEAPS
Mutual Funds
Long-Term Picks
Covered Calls
Weekly Wrap


Interactive Charts
Bookstore
Chat Room


About Us
Advertise
Contact Us
Disclaimer
Terms of Service
 
IRAinvestor.com 02/25/2001

IRA Investing > Covered Calls In association with
By Mark Wnetrzak

From VCR+ to Tissue Re-engineering...
these two look attractive.

Covered Call Legend:
LB-Last Bid price
OI-Open Interest
CB-Cost Basis or break-even point
DE-Days to Expiry
MR-Monthly Return.

GMST - Gemstar $49.50 *** An Old Favorite! ***

Gemstar-TV Guide International Group (NASDAQ:GMST) develops, markets and licenses proprietary technologies and systems that simplify and enhance consumers' interaction with electronics products and other platforms that deliver video, programming information and other data. Their first proprietary system, VCR Plus+, is currently incorporated into virtually every major brand of VCR sold worldwide. The company has also developed and acquired a large portfolio of technologies and intellectual property to implement interactive program guides (Gemstar Guide Technology), which enable consumers to navigate through, sort, select and record television programming.

Gemstar is an OIN favorite as the options premiums are generally robust and the issue has a unique niche in the consumer electronics market. The recently announced a 10-year pact to provide its interactive program guide to U.S. cable operator Charter Communications' (NASDAQ:CHTR) digital cable customers, will provide Gemstar 85% of national advertising revenue. We simply favor the improving technicals and the support above our cost basis.


MAR 40.00 QLF-CH LB=10.88 OI=418 CB=38.62 DE=21 MR=5.2% 


ORG - Organogenesis $10.96 *** Bracing for a Rally ***

Organogenesis (AMEX:ORG) is the only tissue-engineering company to have developed and gained FDA approval for a mass-produced product containing living human cells. The Company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Lead product Apligraf - a cellular, bi-layered skin substitute - is approved and marketed for the treatment of venous leg ulcers and diabetic foot ulcers.

The Organogenesis research pipeline includes the Vitrix(TM) living dermal replacement product, a coronary vascular Graft, and a liver assist device. The stock recently completed a double-bottom formation and is showing increasing strength. Organogenesis continues to report record sales of Apligraf which should bode well for their future earnings.


MAR 10.00 ORG CB LB=1.50 OI=619 CB=9.46 DE=21 MR=8.3%   

 
 
Copyright 2000 - 2001 IRAInvestor.com

Do not duplicate or redistribute in any form.
Privacy Statement   Disclaimer   Terms Of Service